The human-specific nicotinic receptor subunit CHRFAM7A reduces α7 nAChR function in human iPSC-derived and transgenic mouse neurons
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
We investigated the impact of the human-specific protein CHRFAM7A (also referred to as “dupα7”) on the function of α7 nicotinic acetylcholine receptors (nAChRs) in two different types of neurons: human induced pluripotent stem cell (hiPSC)-derived cortical neurons, and superior cervical ganglion (SCG) neurons, taken from transgenic mice expressing CHRFAM7A. CHRFAM7A co-assembles with α7 (also referred to as CHRNA7) but lacks a major part of the extracellular N-terminal ligand-binding domain. We assessed the function of α7 in these preparations with Fura-2 calcium imaging and three different α7-specific ligands: PNU282987, choline, and 4BP-TQS. Given the short-lived open state of α7 receptors, we combined the two orthosteric agonists with the type-2 positive allosteric modulator (PAM II) PNU120596. In line with different cellular models used previously we demonstrate in primary human iPS-derived and in mouse neurons that CHRFAM7A has a major impact on nicotinic α7 receptors by reducing calcium transients in response to all three agonists.